PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.68M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-48.13%
Negative revenue growth while CVE stands at 15.04%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-69.85%
Negative gross profit growth while CVE is at 262.23%. Joel Greenblatt would examine cost competitiveness or demand decline.
-116.77%
Negative EBIT growth while CVE is at 124.80%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-116.77%
Negative operating income growth while CVE is at 124.80%. Joel Greenblatt would press for urgent turnaround measures.
-123.79%
Negative net income growth while CVE stands at 108.11%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-118.55%
Negative EPS growth while CVE is at 108.18%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-118.55%
Negative diluted EPS growth while CVE is at 108.18%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
28.12%
Share change of 28.12% while CVE is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
27.89%
Diluted share count expanding well above CVE's 0.02%. Michael Burry would fear significant dilution to existing owners' stakes.
68.11%
Maintaining or increasing dividends while CVE cut them. John Neff might see a strong edge in shareholder returns.
-5.37%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-198.57%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-83.53%
Negative 10Y revenue/share CAGR while CVE stands at 15.97%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-60.40%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
13.09%
3Y revenue/share CAGR under 50% of CVE's 55.54%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-82.25%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-65.97%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
132.32%
3Y OCF/share CAGR above 1.5x CVE's 62.46%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-115.65%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-228.12%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
55.43%
Below 50% of CVE's 163.22%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
-72.76%
Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
20.07%
5Y equity/share CAGR above 1.5x CVE's 6.17%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
29.76%
Positive short-term equity growth while CVE is negative. John Neff sees a strong advantage in near-term net worth buildup.
-94.27%
Cut dividends over 10 years while CVE stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-66.69%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
48.51%
3Y dividend/share CAGR above 1.5x CVE's 0.89%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
96.71%
AR growth well above CVE's 40.23%. Michael Burry fears inflated revenue or higher default risk in the near future.
No Data
No Data available this quarter, please select a different quarter.
41.32%
Asset growth above 1.5x CVE's 2.33%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
8.58%
Positive BV/share change while CVE is negative. John Neff sees a clear edge over a competitor losing equity.
41.28%
Debt growth far above CVE's 7.49%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
122.44%
We expand SG&A while CVE cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.